In the ever-evolving field of diabetes management, incretin mimetics have emerged as a transformative therapeutic class. Among these, retaglutide, retatrutide, and trizepatide represent advanced additions to the https://kiaraablc683465.blog-a-story.com/20574560/novel-glp-1-receptor-agonists-retaglutide-retatrutide-and-trizepatide